Allergan PLC. (NYSE:AGN) – Analysts at William Blair lowered their Q2 2017 earnings per share estimates for shares of Allergan PLC. in a note issued to investors on Tuesday. William Blair analyst T. Lugo now forecasts that the company will post earnings of $4.00 per share for the quarter, down from their prior forecast of $4.01. William Blair also issued estimates for Allergan PLC.’s FY2018 earnings at $18.14 EPS and FY2019 earnings at $20.60 EPS.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.32 by $0.03. The business had revenue of $3.57 billion during the quarter, compared to analyst estimates of $3.53 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. Allergan PLC.’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the company posted $3.04 EPS.
ILLEGAL ACTIVITY NOTICE: “Equities Analysts Offer Predictions for Allergan PLC.’s Q2 2017 Earnings (AGN)” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://transcriptdaily.com/2017/07/30/equities-analysts-offer-predictions-for-allergan-plc-s-q2-2017-earnings-agn-updated.html.
A number of other research firms have also recently commented on AGN. Citigroup Inc. restated a “focus list” rating and set a $261.27 price target (up from $184.50) on shares of Allergan PLC. in a research note on Friday, April 21st. Deutsche Bank AG restated a “buy” rating and set a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research note on Monday. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a research note on Wednesday, May 10th. Royal Bank Of Canada upped their price target on Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 10th. Finally, Vetr cut Allergan PLC. from a “buy” rating to a “hold” rating and set a $234.38 price target on the stock. in a research note on Monday, June 19th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $273.15.
Shares of Allergan PLC. (NYSE AGN) opened at 246.41 on Thursday. The company has a market capitalization of $82.76 billion, a price-to-earnings ratio of 7.68 and a beta of 1.16. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $261.27. The firm’s 50-day moving average price is $238.93 and its 200-day moving average price is $234.83.
A number of hedge funds have recently bought and sold shares of the stock. Ibex Wealth Advisors acquired a new stake in Allergan PLC. during the fourth quarter worth $538,000. Becker Capital Management Inc. acquired a new stake in Allergan PLC. during the fourth quarter worth $23,304,000. Auxier Asset Management boosted its stake in Allergan PLC. by 16.1% in the fourth quarter. Auxier Asset Management now owns 7,840 shares of the company’s stock worth $1,646,000 after buying an additional 1,090 shares in the last quarter. Kentucky Retirement Systems acquired a new stake in Allergan PLC. during the fourth quarter worth $5,716,000. Finally, Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in Allergan PLC. during the fourth quarter worth $2,550,000. Institutional investors own 84.53% of the company’s stock.
In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.36% of the stock is owned by company insiders.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Allergan PLC. and related companies with MarketBeat.com’s FREE daily email newsletter.